Work

Adapting an immune competent mouse model for glioblastoma T cell therapy

Year: 2014

Type: article

Abstract: Meeting abstracts Glioblastoma (GBM) is the second most common, but most aggressive, primary brain tumor. Despite aggressive multimodal therapy consisting of surgery, radiation, and chemotherapy, the outcome of patients with GBM remains poor with 5-year survival rates of <10%. Therefore, new,

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-2-s3-p35

Authors: Tania Rodriguez-Cruz, Zhongzhen Yi, Stephen Gottschalk, Simone Krebs

Institutions: Baylor College of Medicine, Texas Children's Hospital

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490